Left Menu
Development News Edition

Delhi-based Dr Dangs selected as central lab for Covaxin human clinical trials

"We are extremely privileged to announce that Dr. Dangs Lab, New Delhi has been provided the opportunity to serve the nation by being selected as the central lab for the Human Clinical trials of Covaxin; India's indigenous COVID-19 vaccine being developed and manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV)," it said in a statement. This is a "randomised, double blind, placebo controlled multi-centric clinical trial in India", it added.

PTI | New Delhi | Updated: 23-07-2020 14:46 IST | Created: 23-07-2020 14:46 IST
Delhi-based Dr Dangs selected as central lab for Covaxin human clinical trials

A Delhi-based private laboratory has claimed that it has been selected as the central lab for human clinical trials of Covaxin, India's indigenous COVID-19 vaccine candidate. The vaccine is being developed and manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology.

Dr. Dangs Lab said on Wednesday that it has partnered with Bharat Biotech for conducting the trials. "We are extremely privileged to announce that Dr. Dangs Lab, New Delhi has been provided the opportunity to serve the nation by being selected as the central lab for the Human Clinical trials of Covaxin; India's indigenous COVID-19 vaccine being developed and manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV)," it said in a statement.

This is a "randomised, double blind, placebo controlled multi-centric clinical trial in India", it added. "Dr. Dangs Lab is currently processing all samples for screening and safety for the various phases of this clinical trial, whereas all the efficacy studies will be performed in NIV (Pune)," the statement said.

The lab has already started receiving samples from 50 to 100 subjects per day from various trial sites for safety testing and will be increasing operations as per assigned timelines to cover 12 sites across the length and breadth of the country over this month, it added. "Stringent quality norms driven by good clinical laboratory practice (GCLP) guidelines are being followed as mandated by regulatory authorities. The lab has renowned experts in each field who are working tirelessly and collectively to provide quality and timely results to fulfil the imminent need of an effective and safe COVID19 vaccine," the statement said.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

China: A savior for emerging markets or a poison pill?

... ...

Future of Urban Planning: Artificial Intelligence guiding the way

Advances in emerging technologies like Artificial Intelligence and Machine Learning can help us understand our cities better and derive useful insights from real-time data collected through automated models....

Videos

Latest News

Larsen & Toubro Q3 net profit up 3 pc to Rs 2,648 cr

Engineering and construction giant Larsen Toubro LT on Monday posted a 3 per cent increase in consolidated net profit to Rs 2,648.33 crore for the quarter ended in December 2020.The company had clocked a net profit after tax and share in p...

World News Roundup: China gold miners rescued early after cavities in shaft discovered; China says U.S. military in South China Sea not good for peace and more

Following is a summary of current world news briefs.China gold miners rescued early after cavities in shaft discovered officialEleven Chinese gold miners trapped underground after an explosion were rescued much earlier than expected thanks ...

Loved by students, scholars and writers for 450 years, Oxford pub succumbs to COVID

A historic pub in the centre of Oxford that has served students, scholars and literary greats for over 450 years is to shut down, a cultural casualty of the COVID pandemic.The Lamb and Flag, once frequented by the likes of Lord of the Rings...

Merck ends development of two potential COVID-19 vaccines

The Merck is giving up on two potential COVID-19 vaccines following poor results in early-stage studies. The drugmaker said on Monday that it will focus instead on studying two possible treatments for the virus that also have yet to be appr...

Give Feedback